Copyright
©2005 Baishideng Publishing Group Inc.
World J Gastroenterol. Apr 14, 2005; 11(14): 2072-2079
Published online Apr 14, 2005. doi: 10.3748/wjg.v11.i14.2072
Published online Apr 14, 2005. doi: 10.3748/wjg.v11.i14.2072
Table 1 Expression of HSPs in hepatocarcinogenesis obtained by IHC analysis.
HSP | Percentage of positive cells (%) | NL (n = 57) | DN | HCC | P (r) | ||||
LGDN (n = 11) | HGDN (n = 8) | E-HCC (n = 5) | GI (n = 12) | GII (n = 11) | GIII (n = 10) | ||||
HSP27 | 0-5 | 42 | 11 | 6 | 5 | 2 | 2 | ||
6-25 | 12 | 2 | 4 | 5 | 3 | 3 | 0.0001 | ||
26-50 | 3 | 2 | 1 | (0.600) | |||||
51-75 | 1 | 1 | 2 | ||||||
>75 | 1 | 2 | 4 | ||||||
HSP60 | 0-5 | 1 | |||||||
6-25 | 0.0121 | ||||||||
26-50 | 3 | 3 | (-0.329) | ||||||
51-75 | 2 | 1 | |||||||
>75 | 52 | 11 | 8 | 5 | 12 | 8 | 8 | ||
HSP70 | 0-5 | 57 | 11 | 8 | 3 | 4 | 3 | 2 | |
6-25 | 1 | 3 | 2 | 0.0001 | |||||
26-50 | 1 | 3 | 2 | 1 | (0.669) | ||||
51-75 | 1 | 2 | 4 | ||||||
>75 | 1 | 2 | 3 | ||||||
HSP90 | 0-5 | 56 | 10 | 8 | 5 | 8 | 4 | ||
6-25 | 1 | 1 | 2 | 4 | 3 | 0.0001 | |||
26-50 | 2 | 2 | 3 | (0.707) | |||||
51-75 | 1 | 2 | |||||||
>75 | 2 | ||||||||
GRP78 | 0-5 | 5 | 6 | 1 | 1 | 1 | |||
6-25 | 22 | 5 | 7 | 4 | 5 | 2 | 0.0001 | ||
26-50 | 17 | 1 | 2 | 1 | (0.802) | ||||
51-75 | 9 | 3 | 2 | 1 | |||||
>75 | 4 | 2 | 5 | 8 | |||||
GRP94 | 0-5 | 16 | 3 | 3 | 2 | 1 | 2 | ||
6-25 | 26 | 7 | 4 | 2 | 2 | 0.0001 | |||
26-50 | 9 | 1 | 1 | 1 | 7 | 3 | 2 | (0.708) | |
51-75 | 3 | 1 | 3 | ||||||
>75 | 3 | 1 | 3 | 8 |
Table 2 Expression of HSPs in hepatocarcinogenesis obtained by dot immunoblot analysis.
HSP | Tumor/ non-tumor | DN | HCC | P (r) | ||||
LGDN (n = 11) | HGDN (n = 8) | E-HCC (n = 5) | GI (n = 12) | GII (n = 11) | GIII (n = 10) | |||
HSP27 | < 0.5 | 1 | 1 | |||||
0.5-1.5 | 9 | 6 | 3 | 4 | 4 | 0.0021 | ||
1.5-2.5 | 2 | 1 | 2 | 6 | 2 | 2 | (0.407) | |
> 2.5 | 2 | 3 | 5 | 4 | ||||
HSP60 | < 0.5 | 1 | ||||||
0.5-1.5 | 10 | 6 | 4 | 4 | 5 | 4 | 0.0041 | |
1.5-2.5 | 1 | 2 | 1 | 4 | 6 | 4 | (0.372) | |
> 2.5 | 3 | 2 | ||||||
HSP70 | < 0.5 | |||||||
0.5-1.5 | 6 | 7 | 3 | 3 | 2 | 5 | 0.100 | |
1.5-2.5 | 5 | 2 | 4 | 8 | 4 | (0.220) | ||
> 2.5 | 1 | 5 | 1 | 1 | ||||
HSP90 | < 0.5 | 1 | ||||||
0.5-1.5 | 5 | 6 | 3 | 2 | 2 | 2 | 0.0071 | |
1.5-2.5 | 6 | 2 | 1 | 4 | 7 | 6 | (0.353) | |
> 2.5 | 6 | 2 | 2 | |||||
GRP78 < 0.5 | 1 | 1 | ||||||
0.5-1.5 | 5 | 3 | 3 | 2 | 3 | 2 | 0.0071 | |
1.5-2.5 | 5 | 4 | 1 | 4 | 3 | (0.355) | ||
> 2.5 | 1 | 1 | 6 | 5 | 7 | |||
GRP94 | < 0.5 | 1 | ||||||
0.5-1.5 | 7 | 1 | 2 | 1 | 5 | 4 | 0.571 | |
1.5-2.5 | 2 | 6 | 3 | 5 | 4 | 1 | (0.077) | |
> 2.5 | 2 | 1 | 6 | 2 | 4 |
Table 3 Enhancement of HSP expression relative to non-tumorous tissue in hepatocarcinogenesis obtained by dot immunoblot analysis.
Group | n | Enhancement of expression (mean±SD) | |||||
HSP27 | HSP60 | HSP70 | HSP90 | GRP78 | GRP94 | ||
LGDN | 11 | 1.25±0.31 | 1.07±0.43 | 1.37±0.45 | 1.55±0.45 | 1.65±0.85 | 1.61±1.02 |
HGDN | 8 | 1.22±0.72 | 1.15±0.44 | 1.32±0.58 | 1.20±0.32 | 1.42±0.71 | 2.45±1.87 |
E-HCC | 5 | 2.52±1.57 | 0.93±0.41 | 1.18±0.49 | 1.04±0.64 | 1.72±1.16 | 1.63±0.54 |
HCC GI | 12 | 2.17±1.06 | 1.96±1.20 | 2.69±1.72 | 2.76±1.70 | 7.41±8.65 | 13.70±25.68 |
HCC GII | 11 | 3.26±3.19 | 1.58±0.41 | 1.80±0.55 | 1.95±0.56 | 2.65±1.30 | 1.87±0.90 |
HCC GIII | 10 | 2.68±2.34 | 2.14±1.58 | 1.66±0.84 | 2.22±1.33 | 4.54±4.79 | 3.02±2.70 |
P | 0.0181 | 0.0041 | 0.123 | 0.0211 | 0.0051 | 0.373 |
Table 4 Correlation between HSP immunostaining and prognostic factors in 38 HCCs.
P | ||||||
HSP27 | HSP60 | HSP70 | HSP90 | GRP78 | GRP94 | |
Histological grade | ||||||
E–HCC (5) | ||||||
HCC GI (12) | 0.150 | 0.085 | 0.0091 | 0.0001 | 0.0001 | 0.0001 |
HCC GII (11) | ||||||
HCC GIII (10) | ||||||
Tumor size | ||||||
≤2 cm (10) | 0.097 | 0.158 | 0.077 | 0.079 | 0.0001 | 0.0191 |
>2 cm (28) | ||||||
Encapsulation | ||||||
E-HCC (5) | ||||||
Positive (27) | 0.434 | 0.634 | 0.0491 | 0.0011 | 0.0111 | 0.0051 |
Negative (6) | ||||||
Microvascular invasion | ||||||
Positive (16) | 0.413 | 0.339 | 0.0421 | 0.0001 | 0.0021 | 0.0001 |
Negative (22) | ||||||
Major portal vein invasion | ||||||
Positive (3) | 0.271 | 0.489 | 0.739 | 0.0121 | 0.0501 | 0.0281 |
Negative (35) | ||||||
Intrahepatic metastasis | ||||||
Positive (7) | 0.798 | 0.189 | 0.158 | 0.0001 | 0.0101 | 0.0501 |
Negative (31) | ||||||
Tumor stage I (25) | ||||||
II (10) | 0.800 | 0.816 | 0.128 | 0.0001 | 0.0021 | 0.0001 |
III (3) |
- Citation: Lim SO, Park SG, Yoo JH, Park YM, Kim HJ, Jang KT, Cho JW, Yoo BC, Jung GH, Park CK. Expression of heat shock proteins (HSP27, HSP60, HSP70, HSP90, GRP78, GRP94) in hepatitis B virus-related hepatocellular carcinomas and dysplastic nodules. World J Gastroenterol 2005; 11(14): 2072-2079
- URL: https://www.wjgnet.com/1007-9327/full/v11/i14/2072.htm
- DOI: https://dx.doi.org/10.3748/wjg.v11.i14.2072